Results 31 to 40 of about 75,443 (255)

Age-related results over 2 years of the multicenter Spanish study of atropine 0.01% in childhood myopia progression

open access: yes, 2023
To evaluate the age-related efficacy and safety of atropine 0.01% eye drops over 2 years for myopia control in a multicentric pediatric Spanish cohort. A non-controlled, interventional, prospective multicenter study was conducted as an extension of the ...
Multicenter Group of Atropine Treatment for Myopia Control (GTAM)   +3 more
core   +1 more source

Neuroprotective Effects of Antidotes in Soman-Poisoned Rats

open access: yesActa Medica, 1999
1. The neuroprotective effects of antidotes (atropine, obidoxime/atropine mixture, HI-6/atropine mixture) on rats poisoned with soman at a sublethal dose (48 μg/kg i.m.; 60% of LD50 value) were studied.
Jiří Kassa, Marie Koupilová
doaj   +1 more source

Comparisons of the changes of refractive error and axial length between pre- and post-coronavirus disease in the 0.05% atropine, 0.025% atropine, and 0.01% atropine groups.

open access: yes, 2021
Comparisons of the changes of refractive error and axial length between pre- and post-coronavirus disease in the 0.05% atropine, 0.025% atropine, and 0.01% atropine groups.
Sun Young Shin (1571716)   +2 more
core   +1 more source

Swallowing Disorder and Inhibition of Cough Reflex Induced by Atropine Sulfate in Conscious Dogs

open access: yesJournal of Pharmacological Sciences, 2008
In this study, the effects of atropine sulfate (atropine) on swallowing and cough reflex were evaluated in the two experimental models in conscious dogs.
Tadashi Tsubouchi   +5 more
doaj   +1 more source

Comparison of inhaled atropine sulphate and atropine methonitrate [PDF]

open access: yesThorax, 1980
The bronchodilator potencies of inhaled atropine sulphate and atropine methonitrate have been compared either alone or in combination with fenoterol in a group of adult asthmatic patients. A cumulative dose response study showed that 2 mg of atropine sulphate produced near maximum bronchodilatation.
C J, Allen, A H, Campbell
openaire   +2 more sources

Atropine use in myopia control [PDF]

open access: yes, 2021
Atropine is currently the most effective therapy for myopia control. Recent clinical trials demonstrated low-dose atropine eye drops such as 0.01% resulted in retardation of myopia progression, with less side effects compared to higher concentration ...
Paduca, Ala   +2 more
core  

Topical atropine in retarding myopia progression and axial length growth in children with myopia

open access: yesBangabandhu Sheikh Mujib Medical University Journal, 2020
This study was conducted to observe the effect of atropine in retarding myopia progression and axial length growth in 36 myopic children (atropine group, 24; control, 12). The initial spherical equivalent of the atropine group and control group was -3.0 ±
Abdur Rahman Mohammad Alam   +2 more
doaj   +1 more source

Low-dose AtropIne for Myopia Control in Children (AIM): protocol for a randomised, controlled, double-blind, multicentre, clinical trial with two parallel arms

open access: yesBMJ Open, 2023
Introduction Myopia is a major cause of degenerative eye disease and increases the risk of secondary visual impairment. Mitigating its progression therefore has great potential of clinically relevant benefit as shown by using highly diluted atropine eye ...
Armin Wolf   +26 more
doaj   +1 more source

The action of atropine and acetylcholine on the pace maker ganglion cells of limulus heart

open access: yes, 1960
On the median nerve trunk-heart muscle preparation of Limulus the authors studied the effects of atropine and acetylcholine upon the pace maker ganglion cells.
Yamagami, Matuyosi   +2 more
core   +1 more source

Atropine: Updates on myopia pharmacotherapy

open access: yes, 2022
The prevalence of myopia has rapidly increased over the last 30 years, with the World Health Organization estimating a worldwide incidence of 23%, projected to increase to 50% by 2050.
Marianne L. Shahsuvaryan
core   +1 more source

Home - About - Disclaimer - Privacy